Investors / United States / Medical Excellence Capital
Medical Excellence Capital
Venture capital · Nissequogue, NY, United States · North America
Medical Excellence Capital is an early-stage life sciences venture fund that invests alongside a network of physician-scientists. It also builds and operates companies, using its council of scientists to evaluate opportunities and support portfolio companies.
Invests inHealthcare & Biotech
In its own wordslife sciencesgene therapycell therapysynthetic biologyregenerative medicineai drug discovery
Your fit with Medical Excellence Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsMedical Excellence Capital lists 11 checked portfolio companies on its own site and is named in 4 funding rounds, 1 of them as lead. Its most frequent entry is Series A, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in United States. It invests most often alongside ARCH Venture Partners, RA Capital and 120 Capital.
Counts come from funding rounds that name Medical Excellence Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Medical Excellence Capital's whole history. Rounds on record name 4 companies; its own site lists 11. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 50% |
| Series B | 25% |
| Growth | 25% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 0 |
| '25 | 1 | 0 |
| '26 | 2 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 27th | 11 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 98th | 36% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 19th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| ARCH Venture Partners | 2 |
| RA Capital | 2 |
| 120 Capital | 1 |
| 2048 Ventures | 1 |
| ARK Venture Fund | 1 |
| Agent Capital | 1 |
| Andreessen Horowitz | 1 |
| Astellas Venture Management | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers11100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with ARCH Venture Partners
Compare Medical Excellence Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Medical Excellence Capital| Date | Company | Stage |
|---|---|---|
| 9 Sept 2026 | Series A Led | |
| 10 Jun 2026 | Series B | |
| 20 Nov 2025 | Series C+ | |
| 19 Sept 2024 | Series A |
Round details for Medical Excellence Capital
Amounts, full round histories and every co-investor in Medical Excellence Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
11 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Aspen Neuroscience develops personalized cell therapies for Parkinson's disease using stem cell biology and genomics | Healthcare & Biotech | Nov 2025Series C+ | Page + round | |
| Avilar Therapeutics is developing novel degraders of extracellular proteins as future standard of care medicines for the treatment of multiple serious diseases. | Healthcare & Biotech | Portfolio page | ||
| ClicBio is developing metabolic therapies targeting the hunger pathway | Healthcare & Biotech | Portfolio page | ||
| GC Therapeutics is harnessing a cellular programming platform to overcome development and scaling complexities associated with cell therapy | Healthcare & Biotech | Sept 2024Series A | Page + round | |
| Immunitas Therapeutics discovers and develops novel therapeutics for patients with cancer and autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| Ladder Bio is designing and synthesizing libraries of unique compounds for highly selective binding of proteins of biologic interest | Healthcare & Biotech | Portfolio page | ||
| Pleno Inc. develops and manufactures genomic testing instruments, including the RAPTOR platform, to enable precision medicine at scale. | Healthcare & Biotech | Portfolio page | ||
| ProJenX is developing treatments for ALS and other neurodegenerative diseases | Healthcare & Biotech | Portfolio page | ||
| SonoThera is developing a proprietary, nonviral, non-invasive approach for genetic medicine using ultrasound-mediated delivery | Healthcare & Biotech | Jun 2026Series B | Page + round | |
| Truvian brings comprehensive blood testing directly to the point of care, helping providers act while patients are still present. | Healthcare & Biotech | Portfolio page | ||
| TwoStep Therapeutics is developing tumor-targeted therapies for solid tumors. | Healthcare & Biotech | Sept 2026Series A | Page + round |
About this data
site last read 5 Nov 2026- Site
- medexcelcap.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 19 Sept 2024
- Companies checked
- 11
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Medical Excellence Capital's profile as data
Pull Medical Excellence Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/medexcelcap.com
# also
GET /v1/firms/medexcelcap.com/portfolio
GET /v1/firms/medexcelcap.com/coinvestors
GET /v1/firms/medexcelcap.com/news